
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 07/29/2013

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware
(State or other jurisdiction of
incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition

On July 29, 2013, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the second quarter ended June 30, 2013. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed to "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release, dated July 29, 2013 titled "Dynavax Reports Second Quarter 2013 Financial Results."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: July 29, 2013

By: /s/ Jennifer Lew

Jennifer Lew
Vice President, Finance

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Press Release, dated July 29, 2013 titled "Dynavax Reports Second Quarter 2013 Financial Results."

Contacts:

Jennifer Lew
Vice President, Finance

510-665-7217
jlew@dynavax.com

Michael Ostrach
Vice President and Chief Business
Officer

510-665-7257
mostrach@dynavax.com

DYNAVAX REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS

BERKELEY, CA - July 29, 2013 - Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2013. The Company had \$89.2 million in cash, cash equivalents and marketable securities as of June 30, 2013. This compared to \$125.1 million at December 31, 2012.

For the quarter ended June 30, 2013, Dynavax reported total revenues of \$3.4 million compared to \$2.7 million for the corresponding quarter ended June 30, 2012. Total revenues for the six months ended June 30, 2013 were \$5.5 million compared to \$5.0 million for the same period in 2012.

General and administrative expenses for the quarter ended June 30, 2013 were \$7.6 million. This included significant one-time cash and stock-based severance costs of \$3.0 million. Other than these organizational transition costs, general and administrative expenses decreased by 22% in the quarter.

For the six months ended June 30, 2013, general and administrative expenses were \$16.4 million. This included significant one-time cash and stock-based severance costs of \$5.5 million. Other than these organizational transition costs, general and administrative expenses decreased by 7% when compared to the same period in 2012.

Research and development expenses for the quarter ended June 30, 2013 were \$12.8 million compared to \$11.4 million for the second quarter of 2012. For the six months ended June 30, 2013, research and development expenses were \$27.0 million compared to \$23.8 million for the same period in 2012. This increase was due primarily to manufacturing activities and expenses related to the supply of a HEPLISAV™ component.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

- tables to follow -

DYNAVAX TECHNOLOGIES CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

	Three Months Ended		Six Months Ended	
	<u>June 30,</u>		<u>June 30,</u>	
	<u>2013</u>	<u>2012</u>	<u>2013</u>	<u>2012</u>
Revenues:				
Collaboration revenue	\$ 1,356	\$ 1,623	\$ 2,239	\$ 2,552
Grant revenue	1,395	882	2,155	1,969
Service and license revenue	<u>641</u>	<u>179</u>	<u>1,083</u>	<u>513</u>
Total revenues	3,392	2,684	5,477	5,034
Operating expenses:				
Research and development	12,805	11,376	26,969	23,781

General and administrative	<u>7,636</u>	<u>5,957</u>	<u>16,436</u>	<u>11,750</u>
Total operating expenses	<u>20,441</u>	<u>17,333</u>	<u>43,405</u>	<u>35,531</u>
Loss from operations	(17,049)	(14,649)	(37,928)	(30,497)
Interest income	54	65	126	117
Interest expense	(27)	(589)	(59)	(1,176)
Other income (expense)	<u>(142)</u>	<u>63</u>	<u>(128)</u>	<u>(59)</u>
Net loss	<u>\$ (17,164)</u>	<u>\$ (15,110)</u>	<u>\$ (37,989)</u>	<u>\$ (31,615)</u>
Basic and diluted net loss per share	<u>\$ (0.09)</u>	<u>\$ (0.09)</u>	<u>\$ (0.21)</u>	<u>\$ (0.20)</u>
Shares used to compute basic and diluted net loss per share	<u>182,913</u>	<u>167,697</u>	<u>182,934</u>	<u>161,564</u>

DYNAVAX TECHNOLOGIES CORPORATION
SELECTED CONSOLIDATED BALANCE SHEET DATA

(In thousands)

(Unaudited)

	June 30, <u>2013</u>	December 31, <u>2012</u>
Assets		
Cash, cash equivalents and marketable securities	\$ 89,161	\$ 125,130
Property and equipment, net	8,038	7,965
Goodwill	2,436	2,475
Other assets	<u>4,377</u>	<u>4,182</u>
Total assets	<u>\$ 104,012</u>	<u>\$ 139,752</u>
Liabilities and stockholders' equity		
Deferred revenues	\$ 10,166	\$ 12,068
Other liabilities	<u>9,187</u>	<u>12,858</u>
Total liabilities	19,353	24,926
Stockholders' equity	<u>84,659</u>	<u>114,826</u>
Total liabilities and stockholders' equity	<u>\$ 104,012</u>	<u>\$ 139,752</u>

